EUCTR2007-003684-41-BE进行中（未招募）不适用
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Dose-Ranging Study with Active-Controlled Long-Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in Patients with Primary Hypercholesterolemia orMixed Hyperlipidemia. - Hypercholesterolemia and hyperlipidemia dose ranging study.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient is male or female and 18 to 75 years of age on day of signing informed consent.
- •2.Patient is (a) female and not of reproductive potential or postmenopausal, or (b) female of reproductive potential who agrees to take acceptable contraceptive precautions for the duration of the study.
- •3.Patient is classified as low risk” (0-1 risk factors) according to NCEP/ATPIII cardiovascular risk categories and Framingham risk score with an off-treatment LDL-C value of 100-190 mg/dL (2.6–4.9 mmol/L)
- •4.Patient is classified as moderate risk” (2 or more risk factors and 10 year CHD risk<10%) according to NCEP/ATPIII cardiovascular risk categories and Framingham risk score with an off-treatment LDL-C value of 100-160 mg/dL (2.6–4.1 mmol/L)
- •5.Patient is classified as moderate-high risk” (10-yr CHD risk 10-20%) according to NCEP/ATPIII cardiovascular risk categories and Framingham risk score with
- •an off-treatment LDL-C value of 100-145 mg/dL (2.6–3.6 mmol/L)
- •or, off-treatment LDL-C 100-130 mg/dL (2.6–3.4 mmol/L) if patient was taking lipid therapy more potent than atorvastatin 10 mg at the time of screening (See Appendix 6.3)
- •6.Diabetic patients not taking lipid-lowering medication, with LDL-C 100-130 mg/dL (2.6–3.4 mmol/L), who meet all other entry criteria are eligible
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient has a history of secondary hypertension (high blood pressure), cardiovascular (heart), renal (kidney), neurologic (nervous system), respiratory (lung), hepatic (liver) or metabolic disease. Patient has a history of mental instability or drug/alcohol abuse within the past 5 years. Patient drinks more than 2 alcoholic drinks per day. Patient is pregnant or nursing. Patient is HIV positive. Patient has a history of cancer within the past 5 years. Patient has been in a investigational trial within the last 30 days
研究者
相似试验
已完成
2 期
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired Systolic Functiochronic heart failureNL-OMON46654Bristol-Myers Squibb5
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433Crohn's Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-001225-41-ESAbbVie Deutschland GmbH & Co. KG738
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433EUCTR2017-001225-41-BEAbbVie Deutschland GmbH & Co. KG906
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433Crohn's Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-001225-41-NLAbbVie Deutschland GmbH & Co. KG738
招募中
3 期
A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433form of Inflammatory Bowel Disease (IBD)10017969Crohn's diseaseNL-OMON54751AbbVie B.V.29